Document ID: chunk:federal_register_of_legislation:F2020L01110:reg:9
Version: federal_register_of_legislation:F2020L01110
Segment Type: reg
Provision Reference: reg 9
Character Range: 4332–6474

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of bone and articular cartilage or death from malignant neoplasm of bone and articular cartilage with the circumstances of a person's relevant service:
(1)          having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the affected region at least two years before the clinical onset of malignant neoplasm of bone or articular cartilage;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(2)          having Paget's disease of bone at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage;
(3)          having osteonecrosis at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage;
Note: Osteonecrosis is also known as a bone infarct.
(4)          having chronic osteomyelitis at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage;
(5)          having giant cell tumour of bone at the affected site before the clinical onset of malignant neoplasm of bone or articular cartilage;
(6)          undergoing stem cell or bone marrow transplantation before the clinical onset of malignant neoplasm of bone or articular cartilage;
(7)          taking growth hormone for at least three months before the clinical onset of malignant neoplasm of bone or articular cartilage;
(8)          taking an anthracycline chemotherapeutic agent at least five years before the clinical onset of malignant neoplasm of bone or articular cartilage;
(9)          taking denosumab for at least three months before the clinical onset of malignant neoplasm of bone or articular cartilage, and where taking denosumab has permanently ceased, the clinical onset of malignant neoplasm of bone or articular cartilage has occurred within two years of cessation;
(10)      inability to obtain appropriate clinical management for malignant neoplasm of bone or articular cartilage.